Company Overview
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Why Investors Should Care
Revenue has grown at a 19.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $99.99M (+25.1% YoY); net profit $-21.46M.
- Trailing 12 Months Year-on-year growth — revenue +17.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.44% |
| 1 Year: | 17.10% |
Stock Price Performance
| 1 Year: | +38.52% |
| 6 Months: | -23.15% |
| 3 Months: | -15.62% |
| 1 Month: | -7.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.4% over 5 years.
CONS
- Trading 33.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NPCE NeuroPace, Inc. R2KR3KPHARMA | 12.91 | -27.47 | $443.13M | 0.00% | -18.62% | -103.27% | 19.44% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.97M | 7.64M | 12.77M | 11.22M | 12.63M | 10.34M | 11.37M | 10.20M | 11.16M | 14.47M | 16.51M | 16.43M | 18.12M | 19.26M | 21.06M | 22.52M | 23.52M | 27.35M | 22.07M |
| Gross Profit | 7.06M | 5.42M | 9.57M | 8.49M | 9.36M | 7.51M | 8.26M | 7.47M | 7.96M | 10.37M | 11.97M | 12.23M | 13.34M | 14.13M | 15.42M | 17.34M | 18.13M | 21.17M | 18.05M |
| Operating Income | -5.46M | -3.45M | -1.17M | -3.87M | -4.61M | -6.24M | -9.76M | -10.97M | -10.20M | -8.32M | -7.85M | -5.95M | -7.54M | -6.23M | -4.24M | -5.15M | -6.82M | -2.60M | -5.57M |
| Net Income | -6.74M | -8.79M | -4.13M | -8.81M | -8.49M | -8.08M | -11.46M | -12.69M | -11.79M | -10.38M | -9.12M | -7.26M | -8.93M | -7.51M | -5.45M | -6.59M | -8.65M | -3.50M | -6.69M |
| Diluted EPS | -33.32 | -43.44 | -19.26 | -32.73 | -0.48 | -0.34 | -0.47 | -0.52 | -0.48 | -0.41 | -0.36 | -0.28 | -0.32 | -0.26 | -0.19 | -0.21 | -0.26 | -0.11 | -0.20 |
| R&D Expense | 4.83M | 3.25M | 3.69M | 4.10M | 4.44M | 4.33M | 5.58M | 5.67M | 5.61M | 5.26M | 5.34M | 4.79M | 5.78M | 6.07M | 5.75M | 7.44M | 6.84M | 6.58M | 7.19M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 41.14M | 45.18M | 45.52M | 65.42M | 79.91M | 99.99M |
| Gross Profit | 30.27M | 33.44M | 32.49M | 48.12M | 59.09M | 77.22M |
| Operating Income | -13.05M | -23.74M | -40.79M | -27.17M | -21.67M | -16.34M |
| Net Income | -24.28M | -36.08M | -47.08M | -32.96M | -27.14M | -21.46M |
| Diluted EPS | -117.85 | -2.17 | -1.91 | -1.27 | -0.93 | -0.66 |
| R&D Expense | 15.70M | 18.21M | 21.95M | 20.78M | 23.65M | 27.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 55.95M | 133.56M | 114.11M | 107.65M | 94.65M | 105.56M |
| Total Equity | -129.35M | -147.83M | 73.50M | 34.78M | 20.65M | 8.01M | 19.03M |
| Cash & Equivalents | - | 26.39M | 19.19M | 6.61M | 18.06M | 13.43M | 21.69M |
| Long Term Debt | - | 50.82M | 49.85M | 52.91M | 56.95M | 59.52M | 58.88M |
| Total Liabilities | - | 62.36M | 60.06M | 79.33M | 87.00M | 86.63M | 86.53M |
| Current Liabilities | - | 9.60M | 9.30M | 10.98M | 16.23M | 15.16M | 17.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.61M | -24.58M | -36.87M | -19.70M | -17.95M | -11.01M |
| Investing Cash Flow | -10.77M | -85.40M | 23.80M | 23.03M | 8.99M | -332.00K |
| Financing Cash Flow | 55.01M | 102.53M | 490.00K | 8.13M | 4.33M | 19.60M |
| Capital Expenditure | -62.00K | -384.00K | -603.00K | -173.00K | -306.00K | -332.00K |
| Free Cash Flow | -21.67M | -24.96M | -37.47M | -19.87M | -18.25M | -11.34M |
| Share Buybacks | - | - | - | - | 0 | 49.55M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Operating Margin % | -31.7% | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Net Margin % | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| ROE % | 16.4% | -49.1% | -135.4% | -159.6% | -338.7% | -112.8% |
| ROCE % | -28.2% | -19.1% | -39.6% | -29.7% | -27.3% | -18.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Polar Capital Holdings PLC | 9.61% | 3.30M | $41.79M |
| 2 | Soleus Capital Management, L.P. | 8.48% | 2.91M | $36.88M |
| 3 | First Light Asset Management, LLC | 8.34% | 2.86M | $36.25M |
| 4 | Morgan Stanley | 7.73% | 2.65M | $33.63M |
| 5 | Blackrock Inc. | 7.22% | 2.48M | $31.39M |
| 6 | Orbimed Advisors LLC. | 4.39% | 1.51M | $19.07M |
| 7 | Driehaus Capital Management, LLC | 4.22% | 1.45M | $18.34M |
| 8 | Vanguard Capital Management LLC | 3.57% | 1.23M | $15.55M |
| 9 | Deutsche Bank AG | 2.74% | 938.92K | $11.90M |
| 10 | Armistice Capital, LLC | 2.02% | 692.00K | $8.77M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NPCE
Neuropace, Inc. Estimates – NASDAQ:NPCE - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE44RW5yQkxtQUx1Mnk4ZF9yNndQSkNYY3B1SEZjTzd2WEFZNVN2SnVSa19UOC1FeFVsN2Y1U3l3ekRIaGM5bzZBbG1kZjlFWVlqMktDZDFYU180NDdTWEVlQmNrRzhuVndnMlZDenhoQzA4VTJuczYwNg?oc=5" target="_blank">Neuro…
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNRHE1QnJyTWNXRFhNQzJ6cTg3anFnRm5PeXBDWmlBNF8yX3oteHd1ODgwRWt6YnJ3ckhRdjc2NDdSc2VsZFB2MjNLbkJNUHd3ak5BUlB6bC1OSV9sWjkteGhlVXRYc2l2TVJMWE55eE84WDBCRlozVVByME0zZGk4OVY3dHFGckFyOGo5bz…
NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOWnNSOUE2VHREa1ljUzBNdVdWZmFOZ0ljeUF4Qi0zQWkxV3NkN2hVTWFhekVlcmVOWVZaNEstRzlhQVFjWXpxWHZQUU1SQ1BPdFRKdEJRX1VGVXhhXzJ3ZjhKeV9La2FJY3otQnRQSnc4VkVLQ1ItWldjckFubTJZa2NUdXlCcDhWa2t6em…
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQcnFuWjdCX05WTjNYLXJsTmUtRzVfQzc4dHFpR2pTMjNCVXFCUzV1aGpmSGg2MVRDVGlxQ2R3RE5jb2NrN0tYN0lxNDZrU1JzRjNjRmRiSUpUQ0FhSmQ0QWtKOUM4Q2tSbnpwNmE3TC1iU0Y0MERVTVVZdDR5NEw2b1lXbTVpZHBKd1JFeE…
NPCE Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFA5WVdRM3VtOEpEemxyV1A3Ykk3eUlQemRsRHRnTkZCS2FxWHBCUTFOT1hfMFRwZHFuYUJ1U25McEtrQURXUzhPSnoxNjA0NEtsOU8wUEVSNUx3SVFwSDBFa0dDTnE2SFBBd3N3QTJNNG1pekxKbl9rUXJn?oc=5" target="_blank">NPC…
NeuroPace drops as bid to expand label for RNS System denied in U.S. - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQNHJiR2E1ZzY2UTBzLThnRVl0QlFjVEl6ZldxenUxVTJ6RFdoM1FqMVlJMnhxYnJpWnA1UDVsclB0OFIwNGV5Ykl4Q3NpekpIRGxtN1cxOVhxZVM2Z1p6dVkwbDZ3WnVxc0RjY283Tk9jRlBpcnBWMUtYV3QzUHNHanQ1bkd3X3lQU3B4ZV…
NPCE — Frequently Asked Questions
What is the current share price of NeuroPace, Inc. (NPCE)?
As of 2026-10-23 16:27 PDT, NeuroPace, Inc. (NPCE) trades at $12.91 on NasdaqGM. Its 52-week range is $8.25 to $19.29.
What is the market capitalisation of NPCE?
NeuroPace, Inc. (NPCE) has a market capitalisation of $443.13M on NasdaqGM.
What is the P/E ratio of NPCE?
NPCE trades at a trailing price-to-earnings (P/E) ratio of -27.47. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 41.15.
What is the return on equity (ROE) of NPCE?
NPCE has a return on equity (ROE) of -103.27%. Its return on capital employed (ROCE) is -18.62%.
Is NPCE a good stock to buy?
This page provides a data-driven analysis of NeuroPace, Inc. (NPCE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.